Psychometric attributes of the Scales for Outcomes in Parkinson's Disease-Psychosocial (SCOPA-PS): Validation in Spain and review;Atributos psicométricos de la Scales for Outcomes in Parkinson's Disease-Psychosocial (SCOPA-PS): Validación en España y revisión

Revista de Neurologia

Volumn 49, Issue 1, 2009, Pages 1-7

  Martínez Martín, Pablo ^a   Carroza Garcia E ^a   Frades Payo, B ^a   Rodriguez Blazquez C ^a   Forjaz, M J ^a   De Pedro Cuesta, J ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Evaluation; Parkinson's disease; Psychometric attributes; Psychosocial impact; SCOPA psychosocial

Indexed keywords

AGED; ANALYTICAL ERROR; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PSYCHOMETRY; SOCIAL PSYCHOLOGY; SPAIN; VALIDATION STUDY;

EID: 69349091699     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4901.2009014     Document Type: Article

References (45)

1. Clavería LE, Duarte J, Sevillano MD, Pérez-Sempere A, Cabezas C, Rodríguez F, et al. Prevalence of Parkinson's disease in Cantalejo, Spain: a door-to-door survey. Mov Disord 2002; 17: 242-249
2. Benito-León J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R, Morales JM, Neurological Disorders in Central Spain (NEDICES) Study Group. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 2003; 18: 267-274
3. Jiménez-Jiménez FJ. Epidemiología, etiología y patogenia de la enfermedad de Parkinson. In Obeso JA, Tolosa E, Grandas F, eds. Tratado sobre la enfermedad de Parkinson. 2 ed. Barcelona: Doyma; 2000. p. 117-135
4. Martínez-Suárez MM, Blázquez-Menes B. Estimación de la prevalencia de la enfermedad de Parkinson en Asturias (España). Estudio farmacoepidemiológico del consumo de antiparkinsonianos. Rev Neurol 2000; 31: 1001-1006
5. Bergareche A, De la Puente E, López de Munain A, Sarasqueta C, De Arce A, Poza JJ, et al. Prevalence of Parkinson's disease and other types of Parkinsonism. A door-to-door survey in Bidasoa, Spain. J Neurol 2004; 251: 340-345 (Pubitemid 38387154)
6. Fayers PM, Machin D. Quality of life. The assessment, analysis, and interpretation of patient-reported outcomes. Chichester, UK: John Wiley; 2007. p. 3-30.
7. Marinus J, Visser M, Martínez-Martín P, Van Hilten JJ, Stiggelbout AM. A short psychosocial questionnaire for patients with Parkinson's disease: the SCOPA-PS. J Clin Epidemiol 2003; 56: 61-67 (Pubitemid 36183316)
8. SCOPA-ProPark. http://www.scopa-propark.eu/index.php?page=1&navRight= 7&doc=116&language=eng&teamId=4. [02.12.2008].
9. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752
10. Grupo ELEP. Estudio longitudinal de pacientes con enfermedad de Parkinson (ELEP): objetivos y metodología. Rev Neurol 2006; 42: 360-365 (Pubitemid 47378385)
11. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427-442
12. Marinus J, Visser M, Stiggelbout AM, Martín-Rabey J, Martínez-Martín P, Bonuccelli U, et al. A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry 2004; 75: 388-395 (Pubitemid 38338767)
13. Marinus J, Visser M, Verwey NA, Verhey FR, Middelkoop HA, Stiggelbout AM, et al. Assessment of cognition in Parkinson's disease. Neurology 2003; 61: 1222-1228
14. Friedberg G, Zoldan J, Weizman A, Melamed E. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 1998; 21: 280-284 (Pubitemid 28491427)
15. Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, De Pedro J, on behalf of the Spanish-American Longitudinal PD Patient Study Group. The Clinical Impression of Severity Index for Parkinson's disease: international validation study. Mov Disord 2009; 30: 211-217
16. Visser M, Marinus J, Van Hilten JJ, Schipper RG, Stiggelbout AM. Assessing comorbidity in patients with Parkinson's disease. Mov Disord 2004; 19: 824-828 (Pubitemid 39139596)
17. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992; 41: 237-248
18. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 2004; 19: 1306-1312 (Pubitemid 39534547)
19. Marinus J, Visser M, Van Hilten JJ, Lammers GJ, Stiggelbout AM. Development of a questionnaire for sleep and sleepiness in Parkinson's disease. Sleep 2003; 26: 1049-1054
20. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361-370
21. Marinus J, Leentjens AF, Visser M, Stiggelbout AM, Van Hilten JJ. Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. Clin Neuropharmacol 2002; 25: 318-324 (Pubitemid 36025272)
22. EQ-5D SI Group. EQ-5D SI - a new facility for the measurement of health related quality of life. Health Policy 1990; 16: 199-208.
23. Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D SI -a generic quality of life measure- is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69: 67-73. (Pubitemid 30410417)
24. Smith SC, Lamping DL, Banarjee S, Harwood R, Foley B, Smith P, et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess 2005; 9: 16-19 (Pubitemid 40613705)
25. McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 1995; 4: 293-307.
26. Hays RD, Anderson R, Revicki D. Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 1993; 2: 441-449 (Pubitemid 24035216)
27. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002; 11: 193-205.
28. Eisen M, Ware JE Jr, Donald CA, Brook RH. Measuring components of children's health status. Med Care 1979; 17: 902-921 (Pubitemid 10247183)
29. Ware JE, Gandek B. Methods for testing data quality, scaling assumptions, and reliability: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 945-952 (Pubitemid 28527170)
30. Juniper EF, Guyatt GH, Jaeschke R. How to develop and validate a new health-related quality of life instrument. In Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2 ed. Philadelphia: Lippincott-Raven; 1996. p. 49-56.
31. Beaton DE, Bombardier C, Katz JN, Wright JG. A taxonomy for responsiveness. J Clin Epidemiol 2001; 54: 1204-1217
32. Carod-Artal FJ, Martínez-Martín P, Vargas AP. Independent validation of SCOPA-psychosocial and metric properties of the PDQ-39 Brazilian version. Mov Disord 2007; 22: 91-98 (Pubitemid 46382678)
33. Virués-Ortega J, Carod-Artal FJ, Serrano-Dueñas M, Ruiz-Galeano G, Meza-Rojas G, Velázquez C, et al. Cross-cultural validation of the Scales for Outcomes in Parkinson's Disease-Psychosocial Questionnaire (SCOPA-PS) in four Latin American countries. Value Health 2009; 12: 385-391
34. Martínez-Martín P, Carod-Artal FJ, Da Silveira-Ribeiro L, Ziomkowski S, Vargas AP, Kummer W, et al. Longitudinal psychometric attributes, responsiveness, and importance of change: an approach using the SCOPA-Psychosocial questionnaire. Mov Disord 2008; 23: 1516-1523
35. Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson's disease. Mov Disord 2000; 15: 216-223
36. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69: 308-312
37. Carod-Artal FJ, Vargas AP, Martínez-Martín P. Determinants of quality of life in Brazilian patients with Parkinson's disease. Mov Disord 2007; 22: 1408-1415 (Pubitemid 47280625)
38. Marinus J, Visser M, Jenkinson C, Stiggelbout AM. Evaluation of the Dutch version of the Parkinson's Disease Questionnaire 39. Parkinsonism Relat Disord 2008; 14: 24-27
39. Rodríguez-Blázquez C, Forjaz MJ, Frades-Payo B, De Pedro J, Martínez-Martín P. Independent validation of the Scales for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT). Eur J Neurol 2009 [in press].
40. Martínez-Martín P, Visser M, Rodríguez- Blázquez C, Marinus J, Chaudhuri KR, Van Hilten JJ, on behalf of the SCOPA-Propark and ELEP Groups. SCOPA-sleep and PDSS: two scales for assessment of sleep disorder in Parkinson's disease. Mov Disord 2008; 23: 1681-1688
41. Martínez-Martín P, Frades-Payo B, Rodríguez- Blázquez C, Forjaz MJ, De Pedro Cuesta J, por el Grupo ELEP. Atributos psicométricos de la Scales for Outcomes in Parkinson's Disease-Cognition (SCOPA-Cog), versión en castellano. Rev Neurol 2008; 47: 337-343
42. Martínez-Martín P, Cubo E. Calidad de vida en la enfermedad de Parkinson. In Martínez-Martín P, ed. Calidad de vida en neurología. Madrid: Ars XXI; 2005. p. 203-220
43. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582-592
44. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008; 61: 102-109
45. Wyrwich KW, Wolinsky FD. Identifying meaningful intra-individual change standards for health-related quality of life measures. J Eval Clin Pract 2000; 6: 39-49.